Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 18/20 | 0.86 |
| ▸ | BRD1 | O95696 | 12/20 | 0.86 |
| ▸ | BRPF3 | Q9ULD4 | 11/20 | 0.86 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.86 |
| ▸ | BRD4 | O60885 | 6/20 | 0.86 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.67 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560663 | 0.93 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560691 | 0.89 | BRPF1 (0.89) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17576474 | 0.83 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560720 | 0.81 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL29823517 | 0.81 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560672 | 0.80 | BRPF1 (0.78) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560707 | 0.75 | BRPF1 (0.85) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17576475 | 0.74 | BRPF1 (1.00) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL17560687 | 0.74 | BRPF1 (0.68) | BRPF1BRD1BRPF3BRD9BRD4 | |
| SCHEMBL23318384 | 0.73 | BRPF1 (0.82) | BRPF1BRD1BRPF3BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | BRPF1 104/4885BRD1 4/4885BRPF3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.